Prognostic test to overcome the greatest unmet need in HR+ breast cancer

The greatest unmet need in HR+ breast cancer (BC) patients is the identification of patients at risk of drug resistance and recurrence.  PLA-Dx is an immunohistochemistry-based approach and uses a patented and bespoke proximity ligation assay to identify nuclear estrogen receptor (ER) and progesterone receptor (PR) protein complexes in patient histological specimens.

Key features

  • Identifies patients at risk of recurrence and non-responders to aromatase inhibitors
  • Practical diagnostic compatible with routine pathology systems in hospitals
  • Gives read-out of critical pathway activity and therefore identifies patients who would benefit from novel adjuvant therapies as compared with alternative gene expression tests.

Back to available technologies

Contact us

To enquire about this Available Technology, please contact us.

Contact